Please login to the form below

Not currently logged in
Email:
Password:

Bain Capital

This page shows the latest Bain Capital news and features for those working in and with pharma, biotech and healthcare.

Editas CEO exits the CRISPR firm ahead of first clinical trial

Editas CEO exits the CRISPR firm ahead of first clinical trial

managing director at investment group Bain Capital, and a few months after chief medical officer Gerald Cox also stepped down.

Latest news

  • Pfizer spins out SpringWorks Therapeutics biotech Pfizer spins out SpringWorks Therapeutics biotech

    funding from the drugmaker plus venture capitalists Bain Capital and Orbimed and medical charity LifeArc. ... Pfizer is contributing both equity capital and royalty- and milestone-bearing licenses to the experimental therapies.

  • No deal for Stada as private equity takeover bid collapses No deal for Stada as private equity takeover bid collapses

    Bain Capital and Cinven's planned buyout of Germany's Stada has failed at the last hurdle, with too few of Stada's shareholders agreeing to the deal by the deadline. ... Stada's board had lent its support to the Bain-Cinven offer over a rival 58 per

  • Private equity firms agree deal to take over Stada Private equity firms agree deal to take over Stada

    Cinven and Bain Capital beat out competition from Advent International. The board of German pharma company Stada has agreed to a takeover deal with two of three interested private equity companies, ... Cinven and Bain Capital made what Stada said was the

  • Stada opens books to let formal bidding commence Stada opens books to let formal bidding commence

    Cinven, Advent International and Bain Capital now have opportunity to revise their bids. ... The three interested parties - confirmed as Cinven, Advent International and Bain Capital - will now all receive the "same level of information" and so have the

  • Advent tops Cinven offer for Stada as third suitor looms Advent tops Cinven offer for Stada as third suitor looms

    It has also emerged that the two-horse race has attracted another runner, with a third, non-binding offer from an unnamed company - rumoured to be Bain Capital - matching Advent's ... For months, Stada has been under pressure from rebel investor Active

More from news
Approximately 2 fully matching, plus 8 partially matching documents found.

Latest Intelligence

  • The changing nature of approvals – what does the future hold? The changing nature of approvals – what does the future hold?

    High-profile disinvestments include those by Pfizer and Eli Lilly. However, Pfizer has since announced that, together with investment firm Bain Capital, it has created a new drug company called Cerevel

  • Deal Watch - May 2017 Deal Watch - May 2017

    Intas (pharma). 106. Bain and others. Investment. Dicerna (biotech). 70. M&A without debt. ... 4, 750 (incl. debt). Stada (DE). Bain Capital and Cinven. Company acquisition.

  • Deal Watch February 2017 Deal Watch February 2017

    A third suitor is believed to be another PE firm, Bain Capital.

  • Deal Watch February 2016 Deal Watch February 2016

    A couple of weeks later Stryker paid $1.28bn (approximately 2.5 x sales) to buy Physio-Control from Bain Capital. ... Founded in the 1950s, Physio-Control is a pioneer of defibrillator/monitor technologies and was owned by Lilly and then Medtronic before

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Page & Page

For those who can imagine better, Page & Page is home to meaningful encounters of a marketing, communication and creative kind:...

Latest intelligence

Data desires
What are you looking to achieve with data and how are you preparing yourself to react to the results?...
The balancing act that’s keeping pharma and biotech market access on its toes
Pricing drugs and gaining reimbursement can be a real challenge for drug developers. Price it too high, and no one buys it. Price it too low, and it’s hard to...
Pills
Tackling antimicrobial resistance on multiple fronts
An urgent change of direction is needed in how we respond to AMR...

Infographics